CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 129 enrolled
Drug / intervention
Individualized laboratory testprocedure
Likely dose
Not stated in record
Key inclusion· 3
  • ✓Female
  • ✓Aged 18–35 years, confirmed by government-issued ID
  • ✓Menstrual cycle length 21–35 days on average
Key exclusion· 9
  • ✕Lifetime DSM-5 Axis I disorder (except anxiety and depression)
  • ✕Current DSM-5 depressive or anxiety disorder
  • ✕Positive urine drug screen or breath alcohol concentration >0.00%
  • ✕Current smoker or carbon monoxide concentration ≥6 ppm

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03862469
NCT03862469N/ACompleted
CompareCT.gov

Premenstrual Hormonal and Affective State Evaluation (PHASE) Project

University of Illinois at Chicago·interventional·Posted Mar 5, 2019·Updated Apr 24, 2025

In Brief

A clinical study evaluating Individualized laboratory test for Premenstrual Dysphoric Disorder. Completed, enrolled 129 participants across 1 site.

Detailed Summary

PHASE is designed to evaluate neuroactive hormone trajectories across the menstrual cycle and endocrine, autonomic, and subjective responses to psychosocial stress in women suffering from severe PMS (i.e., premenstrual dysphoric disorder).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPremenstrual Dysphoric Disorder
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMar 5, 2019
Enrollment StartSep 26, 2019
Primary CompletionSep 1, 2023
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 7.3 years ago

Interventions

Individualized laboratory testprocedure

Laboratory test administered between 6 and 2 days prior to the subsequent menstrual cycle.